IN2014DN07813A - - Google Patents
Info
- Publication number
- IN2014DN07813A IN2014DN07813A IN7813DEN2014A IN2014DN07813A IN 2014DN07813 A IN2014DN07813 A IN 2014DN07813A IN 7813DEN2014 A IN7813DEN2014 A IN 7813DEN2014A IN 2014DN07813 A IN2014DN07813 A IN 2014DN07813A
- Authority
- IN
- India
- Prior art keywords
- parameter
- bode
- copd
- prognosis
- pro
- Prior art date
Links
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 2
- 108010048233 Procalcitonin Proteins 0.000 abstract 2
- 239000000090 biomarker Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000012544 monitoring process Methods 0.000 abstract 2
- 102000034567 proadrenomedullin Human genes 0.000 abstract 2
- 108010012004 proadrenomedullin Proteins 0.000 abstract 2
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 abstract 2
- 238000004393 prognosis Methods 0.000 abstract 2
- 238000012502 risk assessment Methods 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 208000000059 Dyspnea Diseases 0.000 abstract 1
- 206010013975 Dyspnoeas Diseases 0.000 abstract 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 abstract 1
- 108010004977 Vasopressins Proteins 0.000 abstract 1
- 102000002852 Vasopressins Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229960003726 vasopressin Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12001590.4A EP2637023A1 (en) | 2012-03-08 | 2012-03-08 | Prediction of outcome in patients with chronic obstructive pulmonary disease |
| PCT/EP2013/000558 WO2013131621A1 (en) | 2012-03-08 | 2013-02-26 | Prediction of outcome in patients with chronic obstructive pulmonary disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN07813A true IN2014DN07813A (enExample) | 2015-07-10 |
Family
ID=47780019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN7813DEN2014 IN2014DN07813A (enExample) | 2012-03-08 | 2013-02-26 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150080246A1 (enExample) |
| EP (3) | EP2637023A1 (enExample) |
| JP (1) | JP6117251B2 (enExample) |
| CN (1) | CN104126125B (enExample) |
| BR (1) | BR112014019349A8 (enExample) |
| DK (1) | DK2823314T3 (enExample) |
| ES (1) | ES2631653T3 (enExample) |
| IN (1) | IN2014DN07813A (enExample) |
| RU (1) | RU2688168C2 (enExample) |
| WO (1) | WO2013131621A1 (enExample) |
| ZA (1) | ZA201405610B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2886979T3 (es) | 2012-02-09 | 2021-12-21 | Memed Diagnostics Ltd | Distintivos y determinantes para diagnosticar infecciones y métodos para usarlos |
| EP2637023A1 (en) | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
| EP3180621B1 (en) | 2014-08-14 | 2020-04-01 | Memed Diagnostics Ltd. | Computational analysis of biological data using manifold and a hyperplane |
| CN106999097B (zh) * | 2014-11-12 | 2021-05-11 | 皇家飞利浦有限公司 | 用于评估受试者中的慢性阻塞性肺疾病copd严重度的装置和方法 |
| CN111624345A (zh) | 2014-12-11 | 2020-09-04 | 米密德诊断学有限公司 | 用于诊断多种感染的标记组合及其使用方法 |
| EP3298402A1 (en) | 2015-05-18 | 2018-03-28 | The University of British Columbia | Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of copd |
| CA3015046A1 (en) | 2016-03-03 | 2017-09-08 | Memed Diagnostics Ltd. | Rna determinants for distinguishing between bacterial and viral infections |
| CN107229813A (zh) * | 2016-03-24 | 2017-10-03 | 深圳中迈数字医疗技术有限公司 | 实施监护的判断方法及系统 |
| CN109804245B (zh) | 2016-07-10 | 2022-10-25 | 米密德诊断学有限公司 | 感染的早期诊断 |
| EP4141448A1 (en) | 2016-07-10 | 2023-03-01 | MeMed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
| WO2018060998A1 (en) | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of prognosis and treatment |
| WO2018060999A1 (en) * | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of risk assessment and disease classification |
| JP7042279B2 (ja) * | 2017-02-02 | 2022-03-25 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有害事象を示すマーカーとしてのｐｒｏａｄｍ |
| CA3059044A1 (en) * | 2017-04-12 | 2018-10-18 | Proterixbio, Inc. | Biomarker combinations for monitoring chronic obstructive pulmonary disease and/or associated mechanisms |
| CN107267658B (zh) * | 2017-08-21 | 2018-11-02 | 常州市第二人民医院 | Copd诊断用分子标志物 |
| US20200300864A1 (en) * | 2017-09-13 | 2020-09-24 | B.R.A.H.M.S Gmbh | Pro-adm as a therapy monitoring marker for critcally ill patients |
| JP7291688B2 (ja) * | 2017-09-13 | 2023-06-15 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 重篤患者における腎置換療法のための指標としてのアドレノメズリン前駆体 |
| CN111094981B (zh) * | 2017-09-13 | 2024-04-16 | B.R.A.H.M.S有限公司 | Pct和pro-adm作为监测抗生素治疗的标记物 |
| EP3502706A1 (en) * | 2017-12-20 | 2019-06-26 | B.R.A.H.M.S GmbH | Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin |
| CN108424969B (zh) * | 2018-06-06 | 2022-07-15 | 深圳市颐康生物科技有限公司 | 一种生物标志物、诊断或预估死亡风险的方法 |
| CN109218131B (zh) * | 2018-09-03 | 2022-03-29 | 平安医疗健康管理股份有限公司 | 网络监控方法、装置、计算机设备和存储介质 |
| US20220196678A1 (en) * | 2019-02-21 | 2022-06-23 | B.R.A.H.M.S. Gmbh | Method for the diagnosis of macce in patients who underwent gastrointestinal surgery |
| FR3094491B1 (fr) * | 2019-03-28 | 2024-07-19 | Rheonova | Méthode in vitro de diagnostic, de stratification, de pronostic et/ou de suivi d'une maladie des poumons et/ou une maladie respiratoire |
| CN110850006B (zh) * | 2019-12-20 | 2020-11-20 | 河南中医药大学 | 一种慢性阻塞性肺病诊断试剂及试剂盒 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| HUE025058T2 (en) * | 2006-05-02 | 2016-01-28 | Critical Care Diagnostics Inc | Differential diagnosis of pulmonary and cardiovascular disease |
| DE102006046996A1 (de) * | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz |
| DE102006053442A1 (de) * | 2006-11-12 | 2008-05-15 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II |
| DE102006060112A1 (de) * | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
| US8815519B2 (en) * | 2006-12-22 | 2014-08-26 | Hvidovre Hospital | Method for predicting cancer and other diseases |
| DE102007021443A1 (de) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels NT-proET-1 |
| HUE029880T2 (en) * | 2008-04-18 | 2017-04-28 | Critical Care Diagnostics Inc | Predicting the risk of serious heart events |
| JP5584695B2 (ja) * | 2008-11-11 | 2014-09-03 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ａｄｍ及びｂｎｐのレベルを決定することによる心疾患に罹患した患者の予後診断及びリスク評価 |
| GB0911007D0 (en) * | 2009-06-25 | 2009-08-12 | Univ Hospital Of North Staffordshire | Analyzer apparatus and methods for lung disease |
| CN102253220B (zh) * | 2011-06-07 | 2014-04-09 | 复旦大学附属中山医院 | 用于诊断慢性阻塞性肺病急性加重期的试剂盒 |
| EP2637023A1 (en) | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
-
2012
- 2012-03-08 EP EP12001590.4A patent/EP2637023A1/en not_active Withdrawn
-
2013
- 2013-02-26 EP EP17000604.3A patent/EP3232201A1/en active Pending
- 2013-02-26 BR BR112014019349A patent/BR112014019349A8/pt not_active Application Discontinuation
- 2013-02-26 DK DK13707113.0T patent/DK2823314T3/en active
- 2013-02-26 US US14/383,744 patent/US20150080246A1/en not_active Abandoned
- 2013-02-26 IN IN7813DEN2014 patent/IN2014DN07813A/en unknown
- 2013-02-26 ES ES13707113.0T patent/ES2631653T3/es active Active
- 2013-02-26 EP EP13707113.0A patent/EP2823314B1/en not_active Revoked
- 2013-02-26 JP JP2014560266A patent/JP6117251B2/ja active Active
- 2013-02-26 CN CN201380009139.6A patent/CN104126125B/zh active Active
- 2013-02-26 RU RU2014140608A patent/RU2688168C2/ru active
- 2013-02-26 WO PCT/EP2013/000558 patent/WO2013131621A1/en not_active Ceased
-
2014
- 2014-07-29 ZA ZA2014/05610A patent/ZA201405610B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013131621A8 (en) | 2014-06-12 |
| BR112014019349A8 (pt) | 2017-07-11 |
| DK2823314T3 (en) | 2017-07-03 |
| CN104126125A (zh) | 2014-10-29 |
| WO2013131621A1 (en) | 2013-09-12 |
| EP2637023A1 (en) | 2013-09-11 |
| EP2823314A1 (en) | 2015-01-14 |
| JP2015509596A (ja) | 2015-03-30 |
| ES2631653T3 (es) | 2017-09-01 |
| BR112014019349A2 (enExample) | 2017-06-20 |
| RU2688168C2 (ru) | 2019-05-20 |
| US20150080246A1 (en) | 2015-03-19 |
| ZA201405610B (en) | 2015-12-23 |
| RU2014140608A (ru) | 2016-04-27 |
| CN104126125B (zh) | 2017-03-01 |
| JP6117251B2 (ja) | 2017-04-19 |
| HK1198556A1 (en) | 2015-05-15 |
| EP2823314B1 (en) | 2017-04-12 |
| EP3232201A1 (en) | 2017-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN07813A (enExample) | ||
| WO2013159872A8 (en) | Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope | |
| MX2013000674A (es) | Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer. | |
| AR098155A1 (es) | Métodos para diagnosticar y tratar trastornos eosinofílicos | |
| MX2016006252A (es) | Tratamiento o prevencion de afecciones pulmonares con monoxido de carbono. | |
| MX2014011254A (es) | Metodo de analisis de riesgo de falla de sistema de perforacion. | |
| NZ716643A (en) | Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event | |
| CA2863393A1 (en) | A multi-biomarker-based outcome risk stratification model for pediatric septic shock | |
| CA3147468C (en) | SYSTEM AND METHOD FOR DETERMINING AN OPTIMAL QC STRATEGY FOR IMMEDIATELY RELEASED RESULTS | |
| IN2012DN06588A (enExample) | ||
| EP3470848A3 (en) | Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides | |
| WO2012122334A3 (en) | Procollagen carboxy-terminal propeptides as a target and treatment for angiogenesis related diseases | |
| RU2010145662A (ru) | Способ прогнозирования риска смерти больных хронической сердечной недостаточностью | |
| IN2012DN02058A (enExample) | ||
| WO2011150509A3 (en) | Diagnosing asthma based on pentraxin-3 | |
| WO2014023808A3 (en) | Method for evaluating a cancer patient for propensity to respond to a therapy | |
| EP3640643A3 (en) | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker | |
| BR112013027080A2 (pt) | método e aparelho para caracterizar integridade de equipamento de controle de processo | |
| WO2012032511A3 (en) | Kit for monitoring, detecting and staging gvhd | |
| UA95606U (uk) | Спосіб прогнозування зрощення перелому | |
| UA82685U (ru) | Способ лечения ложных суставов костей | |
| UA96918U (uk) | Спосіб прогнозування зрощення перелому | |
| UA96501U (uk) | Спосіб прогнозування зрощення перелому | |
| Pillai et al. | A Pilot Study To Investigate The Proteomics Profile Of Asthmatic Patients With Varying Types Of Bronchitis | |
| UA60161U (ru) | Способ прогнозирования риска развития нарушений консолидации переломов |